TUSTIN, Calif., Nov. 13 /PRNewswire-FirstCall/ -- AMDL, Inc. reported today that it has filed a Form 12b-25 with the Securities and Exchange Commission indicating that its Form 10-QSB for the six months ended September 30, 2007 would not be filed by November 14, 2007. However, AMDL expects to file the required report by November 19, 2007, in the time allotted by the Rules. Gary L. Dreher, President, stated: “Accounting for our operations in China is challenging and we need the additional time to properly prepare the Form 10-QSB.”
About AMDL
AMDL, Inc., headquartered in Tustin, California, with operations in Shenzhen, Jaingxi and Jilin China through its wholly owned subsidiary Jade Pharmaceutical Inc., is an international biopharma company. AMDL together with Jade engages in the development, manufacture and marketing of proprietary pharmaceutical and testing products. More information about AMDL and its products can be obtained at http://www.amdl.com.
Forward-Looking Statements
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company’s future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company’s partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.
CONTACT: AMDL Investor Relations, Mr. Paul Knopick, +1-949-707-5365, Voice
Mail, +1-714-505-4460, for AMDL, Inc.
Web site: http://www.amdl.com/
